



Contact: Rehab AlJamal-Naylor  
Tel. +44(0)7919-621 733  
Email: [r.aljamal.naylor@avipero.com](mailto:r.aljamal.naylor@avipero.com)

FOR IMMEDIATE PRESS RELEASE

Monday, 14<sup>th</sup> April 2014.

**AVIPERO Appoints Dr. Samuel Asculai as Senior Advisor.**

EDINBURGH, SCOTLAND- Monday, 14<sup>th</sup> April, 2014-----The board of AVIPERO (Registered in Scotland SC353945) announced today the appointment of Dr. Samuel Asculai as a Senior Advisor.

Dr Asculai is a senior executive with over 30 years of cross-functional experience in the pharmaceutical, chemical and biotechnology industries. His experience combines senior level involvement with large multi-national corporations as well as with a number of successful start-ups. In addition, Dr. Asculai is an achieved scientist and named inventor/coinventor on over 50 issued US patents. He has also an excellent track record in financing where he has raised over \$150 million in financing and have run public as well as private companies in North America, Europe and Australia. Dr Asculai holds a Masters and Doctorate in Microbiology from Rutgers, the State University of New Jersey, was a Visiting Professor in the department of Experimental Pathology at St. Bartholomew's College of Medicine and Dentistry in London and the department of Pathology and department of Orthopaedics at the University of Western Australia. He currently holds senior board positions at OrthoCell, an Australian Regenerative Medicine Company, and Enhance Skin Products, a publically-traded US company specializing in hyaluronan-based skin-care products

"We are delighted to welcome Sam into Avipero's team and we are in no doubt he will have significant and much needed contribution brought about by the culmination of experience and strong track record in the biotech sector." commented Dr. Rehab AlJamal-Naylor, AVIPERO's Chief Scientific Officer.

**About AVIPERO Ltd.**

AVIPERO Ltd (Registered in Scotland SC353945) is a private biopharmaceutical company established in 2009. Avipero is focused on the development of novel therapeutics for unmet clinical needs, characterised by a loss of cells and tissues. This includes conditions such as Parkinson's disease (PD), chronic obstructive pulmonary disease (COPD), arthritis and age related cell decline. AVIPERO has a proprietary first-in-class therapeutic platform covered by a strong intellectual property portfolio. Follow us on Twitter @AVIPERO , LinkedIn:

<http://www.linkedin.com/company/avipero-ltd> and Facebook:  
<https://www.facebook.com/pages/Avipero/211039552252904>

**Forward Looking Statements**

Statements contained herein, other than those which are strictly statements of historical fact may include forward-looking information. Such statements will typically contain words such as "believes", "may", "plans", "will", "estimate", "continue", "anticipates", "intends", "expects", and similar expressions. While forward-looking statements represent management's outlook based on assumptions that management believes are reasonable, forward-looking statements by their nature are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by them. Such factors include, among others, the inherent uncertainty involved in scientific research and drug development, AVIPERO's early stage of development, lack of product revenues, its additional capital requirements, the risks associated with successful completion of clinical trials and the long lead-times and high costs associated with obtaining regulatory approval to market any product which AVIPERO may develop. Other risk factors include the limited protections afforded by intellectual property rights, rapid technology and product obsolescence in a highly competitive environment and AVIPERO's dependence on collaborative partners and contract research organizations. These factors should be considered carefully. Readers are cautioned not to place undue reliance on such forward-looking statements. Similarly, nothing in this press release is meant to promote a pharmaceutical product or make a regulated claim of efficacy.

**FOR FURTHER INFORMATION PLEASE CONTACT:**

Dr. Rehab AlJamal-Naylor  
AVIPERO Ltd  
Director and CSO,  
+44(0)7919-621-733  
info@avipero.com  
[www.avipero.com](http://www.avipero.com)